Evidence map›Paper›PMID 42693483›Full record

ArticleAlzheimer's research & therapy2026

A third-generation, high-affinity biparatopic anti-tau antibody inhibits intracellular tau aggregation seeded by Alzheimer's brain extracts.

Eric Hatterer, Lucile Broyer, Sara Pecoraro, Fabien Cusin, Naz Simsek, John J Breve, Mathieu Clavel, Kevin L Batenburg, Bart Klein, Thuur Zuidweg and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Eric HattererLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Lucile BroyerLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Sara PecoraroSection Clinical Neuroanatomy and Biobanking, Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Fabien CusinLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Naz SimsekSection Clinical Neuroanatomy and Biobanking, Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
John J BreveSection Clinical Neuroanatomy and Biobanking, Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Mathieu ClavelLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Kevin L BatenburgSection Functional Genomics, Department of Human Genetics, UMC - Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Bart KleinSection Functional Genomics, Department of Human Genetics, UMC - Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Thuur ZuidwegSection Clinical Neuroanatomy and Biobanking, Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Kristin PichéStressMarq Biosciences Inc, 118-1537 Hillside Ave, Victoria, BC, V8T 2C1, Canada.
Jeremie BourguignonLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Margot Bonnet-GamardLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Pauline MalingeLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Franck GueneauLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Valery MoineLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Nadia AncerizLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Krzysztof MasternakLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Nicolas FischerLight Chain Bioscience-Novimmune S.A, Geneva, Switzerland.
Torleif Tollefsrud GjølbergAuthera AS, Oslo, 0349, Norway.
Jenny Skjermo TelstadAuthera AS, Oslo, 0349, Norway.
Gaia CalameraAuthera AS, Oslo, 0349, Norway.
Simone MesterAuthera AS, Oslo, 0349, Norway.
Wiep ScheperSection Functional Genomics, Department of Human Genetics, UMC - Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Wilma D J Van de BergSection Clinical Neuroanatomy and Biobanking, Department of Anatomy and Neurosciences, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Jean-Philippe Couradediscoveric bio alpha Ltd, Bahnhofstrasse 1, Schwyz, Pfäffikon, CH-8808, Switzerland. jpc@discovericbio.com.

Funding

discoveric bio alpha ag N/A
6 · The paper itself

Abstract

backgroundTau immunotherapy has recently shown clinical promise but required high dosing. We developed NIDB-3101, a novel third-generation, high-affinity anti-tau biparatopic antibody designed for superior tau binding, aggregation inhibition, and extended half-life.

methodsNIDB-3101 binds tau's microtubule-binding region and C-terminal domains. Various binding and cellular functional assays using recombinants, but more importantly human AD extracts were used to assess NIDB-3101 benefits. Half-life mutations impact was assessed via FcRn binding and cellular assays recycling.

resultsNIDB-3101 exhibited sub-nanomolar affinity, binding a broad spectrum of pathological tau species in AD homogenates, inhibited AD extracts-induced cellular effect compared to benchmark antibodies. Mutations enhanced hFcRn-mediated cellular recycling.

conclusionsNIDB-3101 captures a broad spectrum of pathological tau species leading to strong cellular efficacy using human AD extracts, supporting further clinical development as a potential disease-modifying therapy for AD and related tauopathies.

Indexed as

Alzheimer DiseaseBrainProtein Aggregation, Pathologicaltau ProteinsAnimalsHumanstau ProteinsAlzheimer’s diseaseBiparatopic antibodyBispecific antibodyFcRnHalf-life extensionImmunotherapySeeded aggregationTau

Identifiers

PMID42693483
PMCPMC13543575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.